Dendreon Corporation Shareholders Complain and Vent About Stock Losses at Annual Meeting
Published: Jun 14, 2012
Dendreon shareholders strafed the Seattle biotechnology company's leadership with criticism at Wednesday's annual meeting, upset at the stock's 82 percent decline in the past year. But new CEO John Johnson seemed unruffled by the barrage, and may have scored some points with investors by hinting that Dendreon may find a marketing partner for its Provenge cancer therapy in Europe, rather than going it alone. "You all ought to be fired for cause," longtime stockholder and Seattle resident Charles Heffernan told the management team when he got the microphone.